Sonoma Pharmaceuticals (SNOA) Expected to Announce Earnings on Thursday

Sonoma Pharmaceuticals (NASDAQ:SNOA) will likely be announcing its results before the market opens on Thursday, August 6th. Analysts expect Sonoma Pharmaceuticals to post earnings of ($0.30) per share and revenue of $4.99 million for the quarter.

Sonoma Pharmaceuticals (NASDAQ:SNOA) last released its earnings results on Tuesday, June 16th. The company reported ($0.33) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.09). The business had revenue of $5.56 million during the quarter, compared to analysts’ expectations of $5.57 million. Sonoma Pharmaceuticals had a negative return on equity of 43.95% and a negative net margin of 16.26%.

Sonoma Pharmaceuticals Trading Down 3.5%

NASDAQ SNOA opened at $1.10 on Thursday. The company’s 50-day moving average price is $1.16 and its 200-day moving average price is $1.98. The stock has a market cap of $5.27 million, a PE ratio of -0.58 and a beta of 1.27. Sonoma Pharmaceuticals has a 12 month low of $0.85 and a 12 month high of $6.92.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Sonoma Pharmaceuticals stock. DRW Securities LLC increased its stake in shares of Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) by 257.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 60,977 shares of the company’s stock after purchasing an additional 43,907 shares during the quarter. DRW Securities LLC owned approximately 3.59% of Sonoma Pharmaceuticals worth $222,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 1.95% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Sonoma Pharmaceuticals in a report on Friday, July 24th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has an average rating of “Sell”.

About Sonoma Pharmaceuticals

Sonoma Pharmaceuticals, Inc is a specialty dermatology company focused on developing and commercializing topical prescription and over-the-counter products for inflammatory and infectious skin conditions. Publicly traded on Nasdaq under the symbol SNOA, the company concentrates its efforts on areas such as acne, rosacea, dermatitis and wound care, aiming to provide physicians and patients with innovative treatment options.

At the heart of Sonoma’s technology platform lies its proprietary Triphasic drug delivery system, which enables the timed release of active ingredients through three distinct gel phases.